Nail Cracking |
Baseline |
Week 3 |
Week 4 |
Week 6 |
Week 8 |
Active |
6.7 ± 3.4 |
3.8 ± 3.5 (<.001) |
2.5 ± 3.2 (<.001) |
1.6 ± 2.9 (<.001) |
1.4 ± 2.8 (<.001) |
( improvement) |
|
43.3 |
62.7 |
76.1 |
79.1 |
Placebo |
6.9 ± 2.7 |
3.6 ± 3.4 (.002) |
2.9 ± 3.0 (.004) |
3.0 ± 3.6 (.001) |
2.6 ± 3.6 (.001) |
( improvement) |
|
47.8 |
58.0 |
56.5 |
62.3 |
Nail Brittleness |
Baseline |
Week 3 |
Week 4 |
Week 6 |
Week 8 |
Active |
8.3 ± 1.6 |
4.7 ± 3.0 (<.001) |
2.9 ± 3.4 (<.001) |
1.6 ± 3.1 (<.001) |
1.6 ± 2.7 (<.001) |
( improvement) |
|
43.4 |
65.1 |
80.7 |
80.7 |
Placebo |
7.3 ± 2.0 |
5.0 ± 2.5 (.008) |
3.9 ± 3.1 (.002) |
2.6 ± 3.8 (.001) |
2.3 ± 3.8 (.002) |
( improvement) |
|
31.5 |
46.6 |
64.4 |
68.5 |
Nail Softness |
Baseline |
Week 3 |
Week 4 |
Week 6 |
Week 8 |
Active |
8.1 ± 2.3 |
6.6 ± 2.3 (<.001) |
6.2 ± 2.3 (<.001) |
5.2 ± 2.1 (<.001) |
4.6 ± 2.1 (<.001) |
( improvement) |
|
18.5 |
23.5 |
35.8 |
43.2 |
Placebo |
7.2 ± 1.8 |
6.8 ± 1.7 (NS) |
6.4 ± 1.9 (.08) |
5.4 ± 1.7 (.001) |
5.5 ± 2.2 (.03) |
( improvement) |
|
5.6 |
11.1 |
25.0 |
23.6 |
Hair Dullness |
Baseline |
Week 3 |
Week 4 |
Week 6 |
Week 8 |
Active |
9.1 ± 1.0 |
7.5 ± 1.7 (<.001) |
6.9 ± 1.8 (<.001) |
5.6 ± 2.0 (<.001) |
4.7 ± 2.0 (<.001) |
( improvement) |
|
17.6 |
24.2 |
35.0 |
48.4 |
Placebo |
9.7 ± .65 |
8.7 ± 1.9 (.07) |
8.8 ± 1.8 (.08) |
7.5 ± 2.6 (.01) |
7.5 ± 2.3 (.006) |
( improvement) |
|
10.3 |
9.3 |
22.7 |
22.7 |
Hair Dryness |
Baseline |
Week 3 |
Week 4 |
Week 6 |
Week 8 |
Active |
9.1 ± 1.0 |
6.8 ± 1.7 (<.001) |
6.0 ± 1.6 (<.001) |
5.3 ± 1.7 (<.001) |
4.8 ± 1.7 (<.001) |
( improvement) |
|
25.3 |
34.1 |
41.7 |
47.3 |
Placebo |
9.6 ± .67 |
8.6 ± 1.9 (.046) |
8.3 ± 1.8 (.031) |
7.6 ± 2.3 (.014) |
7.9 ± 1.8 (.013) |
( improvement) |
|
10.4 |
13.5 |
20.7 |
17.8 |
Skin Dryness |
Baseline |
Week 3 |
Week 4 |
Week 6 |
Week 8 |
Active |
6.0 ± 3.1 |
5.5 ± 2.7 (.05) |
5.1 ± 2.3 (.008) |
4.8 ± 2.4 (.007) |
4.7 ± 2.5 (.004) |
( improvement) |
|
8.3 |
15.0 |
20.0 |
21.7 |
Placebo |
7.7 ± 2.8 |
7.0 ± 2.5 (NS) |
6.8 ± 2.6 (.10) |
6.0 ± 3.0 (.003) |
6.2 ± 2.6 (.009) |
( improvement) |
|
9.1 |
11.7 |
22.1 |
19.5 |
|
Figures above were taken using the 10-point rating scale, wherein severity of the problem increases from 1-10, with 1 being least severe and 10 being most severe. |
Table 1: Effects of Active vs. Placebo (represented as mean scores with standard deviations and p-values) on skin, hair and nails. |